Hypopharyngeal Cancer

Hypopharyngeal Cancer
Source: eMedicineHealth.com - Category: General Medicine Source Type: news

Related Links:

Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage IV HPV-Mediated (p16-Positive ) Oropharyngeal Carcinoma AJCC v8;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Oral ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Guo W, Yin G, Liu H, Duan H, Huang Z Abstract The aim of the present study was to analyze the characteristics of angiogenic factors in patients with hypopharyngeal cancer, and to study the effects of these factors on induction chemotherapy, patient prognosis and survival. Data from 60 eligible patients with hypopharyngeal cancer that were treated between January 2012 and December 2016 were collected retrospectively. The differential expression of angiogenic factors in tumor and peritumoral tissues was analyzed retrospectively to assess the association between five differentially expressed genes, including ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
The objective of this study was to use the American College of Surgeons National Cancer Database to examine the association between primary treatment and overall survival among patients with locoregionally advanced hypopharyngeal cancer.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Otolaryngology Source Type: research
CONCLUSIONS: The RP2D of Debio 1143 is 200 mg/day for 14 days, q3w when combined with concomitant high-dose cisplatin chemoradiotherapy in LA-SCCHN. Debio 1143 addition to chemoradiotherapy was safe and manageable. Preliminary efficacy is encouraging and supports further development. PMID: 32994295 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
In conclusion, our results demonstrate for the first time that miR-338-3p targets ADAM17 and blocks the development of hypopharyngeal carcinoma involving the wnt/β-catenin signaling pathway, which may be a new target for clinical intervention in human cancer.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
The temporal effects of topical NF-κB inhibition, in the in vivo prevention of bile-related oncogenic mRNA and miRNA phenotypes in murine hypopharyngeal mucosa: a preclinical model. Oncotarget. 2020 Sep 01;11(35):3303-3314 Authors: Vageli DP, Kasle D, Doukas SG, Doukas PG, Sasaki CT Abstract Supraesophageal bile reflux at strongly acidic pH can cause hypopharyngeal squamous cell cancer, through activation of the oncogenic NF-κB-related pathway. We hypothesize that topical pre- or post-application of pharmacologic NF-κB inhibitor, BAY 11-7082 (0.25 μmol), on murine (C57BL/6J) HM (tw...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
The aim of this retrospective study is to evaluate the usefulness of upper gastrointestinal endoscopy and the Valsamouth Ⓡ by an otolaryngologist in patients with hypopharyngeal cancer to assess the risk.
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Tags: Original Article Source Type: research
ConclusionsEarly stages of laryngeal, oropharyngeal, and hypopharyngeal cancer had a risk of secondary cancer, especially hypopharyngeal cancer. Attention to the secondary cancer has to be paid during the follow-up period after controlling the early-stage disease. These findings highlight the need for awareness of the incidence of secondary cancer in cases of early-stage primary head and neck cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | General Medicine | Hypopharyngeal Cancer